Global Reach, Local Expertise

Cancer Clinical Trials in Miami, Florida

Home   |   Locations   |   United States   |   Miami   |   START Miami

Community Partner

New Cancer Patients

8500

Facility Info

In partnership with Baptist Health South Florida and its Herbert Wertheim Cancer Institute, START Miami brings innovative early-phase oncology clinical trials to patients across the region. Led by Dr. Kyaw Aung, Director of Clinical Research, the site combines START’s global expertise in early-phase oncology drug development with Baptist Health’s extensive clinical network, nationally recognized cancer specialists, and commitment to advancing research. Anchored by Herbert Wertheim Cancer Institute and Lynn Cancer Institute, this collaboration expands access to investigational cancer therapies for patients throughout South Florida, bringing new clinical trial opportunities closer to where they live and receive care.

With a shared commitment to scientific excellence, operational efficiency, and patient-centered care, START Miami leverages START’s global research infrastructure and Baptist Health’s established clinical expertise to accelerate trial activation, support efficient patient enrollment, and deliver high-quality data for sponsors. Fully integrated into START’s global network, the site provides access to an extensive portfolio of early-phase oncology studies while strengthening connections between clinical research and community-based cancer care. Together, START and Baptist Health are advancing a shared mission of Hope Through Access, bringing tomorrow’s cancer treatments closer to patients today.

Explore START Miami's Clinical Trials

Clinical Trials

Explore START Miami's Clinical Trials

If you are interested in participating in a clinical trial at START, we encourage you to reach out to us. Our team will guide you through the process, answer any questions you may have, and help determine if you are eligible for any ongoing trials.

Principal Investigators

The Phase I Clinic

  • 4 Exam Rooms
  • 12 Infusion Chairs
  • PK Lab
  • IDS Pharmacy, including hazardous drug storage and hazardous compounding area
  • Refrigerated / room temperature centrifuges
  • -20°C freezer with continuous temperature monitoring
  • -80°C freezer with continuous temperature monitoring
  • Pharmaceutical-grade refrigerator
  • Crash cart (ACLS certified staff)
  • Infusion/syringe pumps
  • EKG and ECG machine
  • Electronic vital signs monitoring & Accucheck
  • Patient scale
  • All equipment is annually inspected and calibrated

Investigational Drug Section (IDS)

Drug Shipment Address

13400 S.W. 120th St.
Suite 300-A
Miami, FL 33186

Pharmacy Equipment

All equipment is annually inspected and calibrated and includes the following:

    • 2 biological safety cabinets
    • 2 pharmaceutical grade refrigerators
    • 1 pharmaceutical grade -20°C freezer
    • 1 pharmaceutical grade -80°C freezer
    • Secure medication storage with continuous temperature and humidity monitoring

Medication Preparation

Detailed storage, handling and preparation instructions are required.

    • Procedure to prepare investigational drug 
    • Compatible IV bags and syringes
    • Compatible IV tubing and Braun Infusomat pumps
    • Approved closed system transfer device

Medication Screening

  • Clinical research coordinators screen and document pre-study concomitant medications using protocol eligibility criteria and identify prohibited medications and other potential drug interactions of concern.
  • Investigator confirms and signs off on eligibility.

Drug Accountability

  • Master accountability log maintained for each study.
  • Due to the potential for staff exposure to hazardous materials, the IDS will not maintain any empty or partially empty container left from the preparation of investigational doses. This includes both IV and PO dosage forms.

Pharmacokinetics

PK Shipment Address

13400 S.W. 120th St.
Suite 300-A
Miami, FL 33186

Laboratory Equipment

All equipment is annually inspected and calibrated and includes the following:

    • Refrigerated / room temperature centrifuges
    • -80°C freezer with continuous temperature monitoring
    • -20°C freezer with continuous temperature monitoring

Shipping Capabilities

Staff processing PK samples are IATA shipping certified. Specimens may be shipped same day, weekly, or monthly.

Biopsy Specimens

Staff processing PK samples are present at the time of biopsy at ASC and ship tissue according to protocol requirements or send to pathology lab for processing based on protocol requirements.

Archival Specimens

  • Staff request and process archival specimens
  • Unstained slides are obtained and sent to sponsor or designee
  • Tumor blocks and slides are obtained based on pathology lab policy

Specialty Labs

  • PK department staff routinely process and ship to Central Lab specimens such as biomarkers, PBMCs, DNA, hair follicle specimens, and other specialty labs.

Regulatory Affairs & Data Management

Data Entry Capabilities

  • Every study has a dedicated START Clinical Research Assistant (CRA). 
  • START has experience with a wide variety of electronic data capture systems (i.e., Medidata RAVE, InForm, Tempo, DataTrak, etc.). 
  • START ensures clean, accurate, and timely data entry and query resolution. 
    • 10 business days for data entry 
    • 5 business days for query resolution

On-site Monitoring Area

  • 1 monitoring workstations with high-speed Internet and computer for accessing the EMR
  • Wi-Fi is available for EDC access
  • Basic office supplies, copier, and telephone are available
  • On-site monitoring hours are Monday – Friday, 8am – 3pm ET, with flexibility

Remote Monitoring Services

  • START’s remote monitoring service allows the monitor to have access to our EMR and e-ISF (Veeva) systems without having to be on-site. 
  • Remote monitoring hours are Monday – Friday, 8am – 3pm ET, with flexibility, provided that any adjustments are agreed upon between the coordinators and the monitors.

Scheduling Monitoring Visits

  • The START Regulatory Coordinator is the main point of contact for the scheduling of all on-site and/or remote monitoring visits (i.e., initial, interim, and close-out visits, etc.).
  • Monitor visits must be scheduled at least 30 days in advance (recommended 6 weeks).
  • Requests for co-monitors must be reviewed by the study team and approved by the Principal Investigator.

Hybrid Monitoring

Monitors will be required to conduct onsite and remote visits during the following times: 

    • First monitoring visit and once per quarter may be conducted onsite.
    • All other visits will be conducted remotely.

Contact

Get in Touch

Let’s save lives—together. Fill out the form to connect with us today, whether you’re ready to jump in or just have questions. Every action counts.

Other Locations